Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Kurshumliu, Fisnik ^a,d   Gashi Luci, Lumturije ^a   Kadare, Shahin ^b   Alimehmeti, Mehdi ^c   Gozalan, Ugur ^d  

^a UNIVERSITY OF PRI TINA   (Serbia)

^b Laboratori Diagnostik Morfopatologjik   (Albania)

^c She¨rbimi i Anatomise¨Patologjike Qendra Spitalore Universitare Ne¨naTereze¨ ^*  (Albania)

^d American Hospital Kosova   (Serbia)

Author keywords

Breast cancer; Immunohistochemistry; Nottingham prognostic index

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; AXILLARY DISSECTION; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; NOTTINGHAM PROGNOSTIC INDICATOR; PATIENT CODING; BREAST TUMOR; CLASSIFICATION; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905903654     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-243     Document Type: Article

References (28)

1. Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer 2014, 110:1688-1697.
2. Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR, Ellis IO. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer 2013, 109:1886-1894.
3. Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, Macmillan RD, Blamey RW, Ball G, Lisboa PJ, Etchells TA, Boracchi P, Biganzoli E, Ellis IO. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 2010, 40:318-330.
4. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12:207.
5. Sundquist M, Thorstenson S, Brudin L, Nordenskjo¨ld B. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999, 53:1-8.
6. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
7. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
8. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-10398.
9. Chen C, Dhanda R, Tseng W-Y, Forsyth M, Patt DA. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract Am Soc Clin Oncol 2013, 9:182-187.
10. De Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Med J Aust 2013, 199:205-208.
11. Carlson JJ, Roth JA. The impact of the OncotypeDx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013, 141:13-22.
12. Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010, 28:969-977.
13. DeFrank JT, Salz T, Reeder-Hayes K, Brewer NT. Who gets genomic testing for breast cancer recurrence risk?. Public Health Genomics 2013, 16:215-222.
14. Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev 2014, 40:434-444.
15. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
16. Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008, 26:3153-3158.
17. Blamey RW, Ellis IO, Pinder SE, Lee AHS, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 19901999. Eur J Cancer 2007, 43:1548-1555.
18. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med 2010, 134:907-922.
19. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013, 31:3997-4013.
20. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thu¨rlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.
21. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006, 12:2468-2475.
22. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006, 8:R48.
23. Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, Han W, Park IA, Noh DY. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer 2012, 131:1109-1119.
24. Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep 1998, 5:1211-1216.
25. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
26. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994, 54:2095-2097.
27. Alsabeh R, Wilson CS, Ahn CW, Vasef MA, Battifora H. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 1995, 9:439-444.
28. Vogelstein B, Kinzler KW. Achilles' heel of cancer?. Nature 2001, 412:865-866.